In recent decades, respiratory disorders such as asthma, COPD, and respiratory infections have significantly impacted global health. In response, pharmaceutical innovation is accelerating to address these challenges.
Respiratory diseases are among the leading causes of death and disability. WHO reports that over 262 million people had asthma in 2019 and more than 3 million died due to COPD. These alarming numbers call for advanced treatment strategies.
Factors contributing to rising cases include air pollution, tobacco use, workplace hazards, aging populations, and genetic predispositions.
Respiratory formulations deliver drugs directly to the lungs via:
These methods ensure fast action, fewer side effects, and better adherence — but require precision in formulation and delivery technology.
BoV sprays use compressed air instead of chemical propellants, offering precision, eco-friendliness, and 360-degree spraying. Legency Remedies explores this for nasal and aerosol products.
Blow-Fill-Seal (BFS) containers ensure sterile, single-dose respiratory formulations. Ideal for bronchodilators and anti-inflammatories in hospitals and pediatric use.
Advanced micronization produces ideal particle sizes for deep lung penetration, enhancing bioavailability and treatment efficiency. Legency uses this for MDIs and DPIs.
Combining corticosteroids with bronchodilators improves asthma/COPD outcomes. Legency is formulating such therapies for better compliance and control.
As a WHO-GMP and ISO-certified company, Legency Remedies manufactures high-quality respiratory products in Baddi, including:
They're committed to sustainable production and international collaboration to bring innovative care worldwide.
Innovations in respiratory drug delivery, such as BoV, BFS, and combination therapies, are improving outcomes and access. Legency Remedies is a key player, combining science, quality, and technology to deliver better respiratory care for all.
